PFE Stock Recent News

Pfizer Inc (NYSE:PFE, ETR:PFE) has agreed a licensing deal worth up to $6 billion with Chinese biopharmaceutical group 3SBio to develop and commercialise an experimental cancer treatment. The drug, SSGJ-707, is currently in clinical trials in China for use against lung, colorectal and gynaecological cancers.

Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug undergoing trials for treatment of certain types of cancer and tumours, the U.S. drugmaker said on Monday.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. SSGJ-707 has shown initial e.

I'm recommending two beaten-down REITs, American Assets Trust and Alexandria Real Estate, as long-term dividend plays with strong fundamentals and well-covered yields. Both stocks face near-term headwinds, but offer attractive entry points for patient investors seeking multi-year recovery and income. AAT is undervalued due to office exposure and California concentration, but has solid financials, a safe dividend, and multifamily growth potential.

Both PFE and MRK have strong product and pipeline portfolios in oncology.

16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio TOKYO , May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3). The research underscores Astellas' dedication as a pioneer in oncology and focus on clinical outcomes that matter to patients.

Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.

Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal.

On April 29, 2025, Pfizer beat consensus EPS estimates for the twelfth consecutive quarter by a wide margin, creating a divergence with its stock price, which continues to move sideways. I was pleasantly surprised by the strong performance of Pfizer's oncology and cardiovascular franchises, as well as the positive effects of its cost-cutting program. So, the Vyndaqel family's sales amounted to about $1.49 billion, increasing by 30.7% year-on-year, despite competition from BridgeBio's Attruby and Alnylam Pharmaceuticals' Amvuttra.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.